Xeris Biopharma (NASDAQ:XERS) Insider Steven Pieper Sells 5,000 Shares of Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Steven Pieper sold 5,000 shares of Xeris Biopharma stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $8.50, for a total value of $42,500.00. Following the completion of the transaction, the insider directly owned 1,356,053 shares in the company, valued at approximately $11,526,450.50. This represents a 0.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

• On Wednesday, August 12th, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.50, for a total value of $42,500.00.
• On Tuesday, July 7th, Steven Pieper sold 27,600 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.52, for a total transaction of $235,152.00.
• On Monday, July 6th, Steven Pieper sold 17,400 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.50, for a total transaction of $147,900.00.

Xeris Biopharma Trading Down 0.1%

Shares of XERS stock opened at $8.43 on Wednesday. The firm has a market capitalization of $1.54 billion, a P/E ratio of -76.64 and a beta of 0.66. Xeris Biopharma Holdings, Inc. has a 1 year low of $5.25 and a 1 year high of $10.08. The firm’s fifty day simple moving average is $8.34 and its 200 day simple moving average is $6.95. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). The company had revenue of $92.10 million during the quarter, compared to the consensus estimate of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. As a group, sell-side analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current year.

Hedge Funds Weigh In On Xeris Biopharma

A number of hedge funds have recently modified their holdings of XERS. Kestra Advisory Services LLC acquired a new stake in Xeris Biopharma in the 4th quarter valued at $25,000. KBC Group NV acquired a new position in Xeris Biopharma during the first quarter worth $27,000. Allworth Financial LP acquired a new position in Xeris Biopharma during the second quarter worth $34,000. State of Wyoming bought a new position in shares of Xeris Biopharma during the second quarter valued at $52,000. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in shares of Xeris Biopharma by 9,276.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock valued at $59,000 after acquiring an additional 7,421 shares during the period. 42.75% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

XERS has been the topic of several research reports. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Barclays lifted their price objective on Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Finally, Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $12.00.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.